Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma

Abstract

Aim: Inflammation-based markers, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), have recently been used as prognostic indicators in hepatocellular carcinoma (HCC). We aimed to determine whether NLR and PLR may predict response to yttrium-90 transarterial radioembolization (TARE) as primary treatment for HCC.

Methods: We performed a retrospective review of a prospectively collected database of HCC cases (1994-2019) and selected patients who received TARE as primary treatment (n = 42). Laboratory studies were used to calculate NLR and PLR. Response to TARE was determined using the modified response evaluation criteria in solid tumors (mRECIST). Patients were classified as non-responders (stable or progressive disease) or responders (partial or complete response) to treatment based on mRECIST.

Results: Receiver operating characteristic curves identified a pre-treatment NLR cutoff of ≥ 2.83 and a pre-treatment PLR cutoff of ≥ 83 for predicting non-response to treatment. Pre-treatment NLR ≥ 2.83 was the only significant predictor of non-response to TARE in multivariate logistic regression analysis (odds ratio 7.83, P = 0.036). On time to progression analysis, both pre-treatment NLR ≥ 2.83 and pre-treatment PLR ≥ 83 were associated with a higher proportion of tumor progression at 6 months post-treatment (43.6% vs. 10.0%, P = 0.014, log-rank) and (38.6% vs. 0%, P = 0.010, log-rank), respectively.

Conclusion: NLR confers prognostic value and may be superior to PLR in determining response to TARE as primary treatment for HCC. Future studies are necessary to validate these findings in a larger cohort.

Keywords

Neutrophil-to-lymphocyte ratio / platelet-to-lymphocyte ratio / transarterial radioembolization / hepatocellular carcinoma

References

[1] Yang JD,Gores GJ,Plymoth A.A global view of hepatocellular carcinoma: trends, risk, prevention and management..Nat Rev Gastroenterol Hepatol2019;16:589-604 PMCID:PMC6813818

[2] McGlynn KA.The global epidemiology of hepatocellular carcinoma: present and future..Clin Liver Dis2011;15:223-43vii-x PMCID:PMC4141529

[3] Salem R,Mouli S,Kallini J.Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma..Gastroenterology2016;151:1155-63.e2 PMCID:PMC5124387

[4] Moreno-Luna LE,Sanchez W,Harnois DM.Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma..Cardiovasc Intervent Radiol2013;36:714-23 PMCID:PMC3594060

[5] Carr BI,Buch SC.Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study..Cancer2010;116:1305-14 PMCID:PMC2829376

[6] Lencioni R.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma..Semin Liver Dis2010;30:52-60

[7] Duvoux C,Decaens T,Badran H.Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria..Gastroenterology2012;143:986-94.e3quiz e14-5

[8] Berry K.Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma..Liver Transpl2013;19:634-45

[9] Tateishi R,Matsuyama Y,Kondo Y.Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review..Hepatol Int2008;2:17-30 PMCID:PMC2716871

[10] Li J,Yu X,Yang G.Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA..J Exp Clin Cancer Res2018;37:213 PMCID:PMC6122633

[11] Templeton AJ,Šeruga B,Aneja P.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis..J Natl Cancer Inst2014;106:dju124

[12] Qi X,Deng H,Su C.Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: a systematic review and meta-analysis of observational studies..Oncotarget2016;7:45283-301 PMCID:PMC5216723

[13] Templeton AJ,McNamara MG,Vera-Badillo FE.Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis..Cancer Epidemiol Biomarkers Prev2014;23:1204-12

[14] Li C,Yan LN,Wang WT.Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma..J Surg Res2015;198:73-9

[15] Grivennikov SI,Karin M.Immunity, inflammation, and cancer..Cell2010;140:883-99 PMCID:PMC2866629

[16] Buergy D,Groden C.Tumor-platelet interaction in solid tumors..Int J Cancer2012;130:2747-60

[17] Greten FR.Inflammation and Cancer: Triggers, mechanisms, and consequences..Immunity2019;51:27-41 PMCID:PMC6831096

[18] Motomura T,Mano Y,Toshima T.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment..J Hepatol2013;58:58-64

[19] Pinato DJ.An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma..Transl Res2012;160:146-52

[20] Tian XC,Zeng FR,Wu DH.Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolization..Eur Rev Med Pharmacol Sci2016;20:2302-9

[21] Taussig MD,Mouli SK,Geevarghese S.Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma..HPB (Oxford)2017;19:458-64

[22] Soydal C,Nak D,Baltacioğlu MH.Analysis of prognostic factors in patients receiving transarterial radioembolization for unresectable hepatocellular carcinoma..Nucl Med Commun2020;41:73-7

[23] Sukato DC,Chalhoub D,Zajko A.The prognostic role of neutrophil-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma treated with radioembolization..J Vasc Interv Radiol2015;26:816-24.e1

[24] D’Emic N,Molitoris J,Sharma NK.Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy..J Gastrointest Oncol2016;7:269-77 PMCID:PMC4783753

[25] Johnson PJ,Kagebayashi C,Teng M.Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade..J Clin Oncol2015;33:550-8 PMCID:PMC4322258

[26] Gui B,Nosher J,Foltz GM.Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization..Am J Clin Oncol2018;41:861-6 PMCID:PMC5645222

[27] Mohammadi H,Jin W,Friedman M.Using the albumin-bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma..J Gastrointest Oncol2018;9:840-6 PMCID:PMC6219966

[28] Coffelt SB,de Visser KE.Neutrophils in cancer: neutral no more..Nat Rev Cancer2016;16:431-46

[29] Yan M.The role of platelets in the tumor microenvironment: from solid tumors to leukemia..Biochim Biophys Acta2016;1863:392-400

[30] Ménétrier-Caux C,Blay JY.Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?.J Immunother Cancer2019;7:85 PMCID:PMC6437964